Arthur A.
Arthur A. Beisang, White Bear Lake, MN US
Patent application number | Description | Published |
---|---|---|
20090214611 | Implant Filling Material and Method - Compositions of cross-linked polyvinylpyrrolidone (PVP) are disclosed that are generally in the form of an elastic, hydrophilic, water-insoluble viscous cohesive mass of material that has many important medical uses including uses as a filler for implants. The present invention also involves a process for producing such compositions. | 08-27-2009 |
20090278660 | CREDIT CARD PROTECTION SYSTEM - The present invention provides positive protection for the machine readable credit card, debit card, etc., against theft by eliminating the presence of visible identifying and correlating information on the credit card or debit card itself until the card is activated by a wireless biometric verification system. The preferred mode of verification includes fingerprint data from the user. | 11-12-2009 |
20090306245 | Implant Filling Material and Method - Compositions of cross-linked polyvinylpyrrolidone (PVP) are disclosed that are generally in the form of an elastic, hydrophilic, water-insoluble viscous cohesive mass of material that has many important medical uses including uses as a filler for implants. The present invention also involves a process for producing such compositions. | 12-10-2009 |
20100316689 | Implant Filling Material and Method - Compositions of cross-linked polyvinylpyrrolidone (PVP) are disclosed that are generally in the form of an elastic, hydrophilic, water-insoluble viscous cohesive mass of material that has many important medical uses including uses as a filler for implants. The present invention also involves a process for producing such compositions. | 12-16-2010 |
Arthur A. Beisang, Iii, North Oaks, MN US
Patent application number | Description | Published |
---|---|---|
20090214611 | Implant Filling Material and Method - Compositions of cross-linked polyvinylpyrrolidone (PVP) are disclosed that are generally in the form of an elastic, hydrophilic, water-insoluble viscous cohesive mass of material that has many important medical uses including uses as a filler for implants. The present invention also involves a process for producing such compositions. | 08-27-2009 |
20090306245 | Implant Filling Material and Method - Compositions of cross-linked polyvinylpyrrolidone (PVP) are disclosed that are generally in the form of an elastic, hydrophilic, water-insoluble viscous cohesive mass of material that has many important medical uses including uses as a filler for implants. The present invention also involves a process for producing such compositions. | 12-10-2009 |
20100316689 | Implant Filling Material and Method - Compositions of cross-linked polyvinylpyrrolidone (PVP) are disclosed that are generally in the form of an elastic, hydrophilic, water-insoluble viscous cohesive mass of material that has many important medical uses including uses as a filler for implants. The present invention also involves a process for producing such compositions. | 12-16-2010 |
Arthur A. Evans, Culver City, CA US
Patent application number | Description | Published |
---|---|---|
20140150534 | SCANNING NON-CONTACT SURFACE MICRORHEOMETER - The disclosure provides non-contact microrheological methods that can measure the fluctuation of a particle in a monolayer, where the particle is hydrodynamically coupled to the monolayer. The disclosure further comprises devices to carry out the non-contact microrheological methods thereof, including Laser Tweezer devices which can study in vitro biological processes. | 06-05-2014 |
Arthur A. Gaplanyan, North Hollywood, CA US
Patent application number | Description | Published |
---|---|---|
20130211567 | SYSTEM AND METHOD FOR PROVIDING AUDIO CONTENT ASSOCIATED WITH BROADCASTED MULTIMEDIA AND LIVE ENTERTAINMENT EVENTS BASED ON PROFILING INFORMATION - A system and method for providing primary and secondary audio content over a wireless network at a public or private forum to at least one mobile audio receiver device includes receiving the primary audio content from a content provider over a corresponding communications path; transmitting selected primary audio content from the communications path continuously over the wireless network to the receiver; terminating transmission of the selected primary audio content to the receiver at predetermined time intervals or on-demand; transmitting the secondary audio content over the wireless network to the receiver while the selected primary audio content transmission is terminated, the secondary audio content being transmitted for a second predetermined time interval or on-demand; and transmitting the selected primary audio content from the corresponding communications path over the wireless network to the receiver after the secondary audio content being transmitted for a second predetermined time interval or on-demand has terminated. | 08-15-2013 |
Arthur A. Getzman, Flemington, NJ US
Patent application number | Description | Published |
---|---|---|
20140072629 | BIOLOGIC MATRICES COMPRISING ANTI-INFECTIVE, METHODS AND COMPOSITIONS RELATED THERETO - Described herein are methods and compositions related to biologic matrices comprising at least one anti-infective. In certain embodiments, the invention relates to a biologic matrix comprising a slowed release anti-infective agent. In a particular embodiment, the invention relates to an acellular dermal matrix comprising a slowed release anti-infective agent, wherein the anti-infective agent is triclosan. In further embodiments, the invention relates to a biologic matrix comprising at least one anti-infective agent, wherein the biologic matrix is suitable for use in surgical procedures, such as, for example, for the replacement of damaged or inadequate integumental tissue or for the repair, reinforcement or supplemental support of soft tissue defects. | 03-13-2014 |
Arthur A. Gibeaut, Erie, IL US
Patent application number | Description | Published |
---|---|---|
20110168655 | USE OF NO-BAKE MOLD PROCESS TO MANUFACTURE RAILROAD COUPLERS - A railroad coupler assembly having at least a body and a knuckle both formed in a no-bake manufacturing process, the body and the knuckle having dimensional tolerances of distances between features that wear during operation that are about half those obtained from a body and a knuckle manufactured by a green sand process, resulting in increased fatigue life compared to the body and the knuckle manufactured by a green sand process. | 07-14-2011 |
20130269900 | USE OF NO-BAKE MOLD PROCESS TO MANUFACTURE RAILROAD COUPLERS - A railroad coupler assembly having at least a body and a knuckle both formed in a no-bake manufacturing process, the body and the knuckle having dimensional tolerances of distances between features that wear during operation that are about half those obtained from a body and a knuckle manufactured by a green sand process, resulting in increased fatigue life compared to the body and the knuckle manufactured by a green sand process. The body and the knuckle resulting from the no-bake manufacturing process have no observable laps, scabs, chaplets or welding in critical areas of the body and knuckle, which are reflected in surface conditions matching SCRATA (Steel Castings Research and Trade Association) values of: D1 (laps); E1 (scabs); F1 (chaplets); and J1 (welds). | 10-17-2013 |
20150048044 | USE OF NO-BAKE MOLD PROCESS TO MANUFACTURE RAILROAD COUPLERS - A railroad coupler assembly having at least a body and a knuckle both formed in a no-bake manufacturing process, the body and the knuckle having dimensional tolerances of distances between features that wear during operation that are about half those obtained from a body and a knuckle manufactured by a green sand process, resulting in increased fatigue life compared to the body and the knuckle manufactured by a green sand process. | 02-19-2015 |
Arthur A. Goikhman, Morganville, NJ US
Patent application number | Description | Published |
---|---|---|
20090094107 | Enhanced Ad-Wrapped Applications for Mobile and Other Computing Devices - An application, executing on a mobile or other computing device, which has been subject to wrapping technology, provides the wrapper with the ability to insert logos, banners, and other advertising material, and allows that advertising information to be displayed within the wrapped application, not just before and after execution of the application. By having the wrapper specify the advertising images and data to be used, the in-application advertisements can complement the advertisements the wrapper displays before and after the application is executed. | 04-09-2009 |
Arthur A. Klipfel, Iii, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20120197603 | Computer Code and Method for Designing a Multi-Family Dwelling - A collection of dwelling unit module designs is created from which multi-family dwelling buildings or the multi-family portion of a mixed-use building may be designed. The module designs each fit onto uniform grid intervals defining a structural support system which may fit a parking layout below the units. A module design may include an individual unit or a stack of units. A graphical user interface to a computer system accommodates defining a site specific outline for the building and filling the outline with dwelling unit modules from the collection. The dwelling unit module designs may be designed and perfected in a manner independent of and in advance of any specific project and project schedule. | 08-02-2012 |
Arthur A. Oubrie, Wijchen NL
Patent application number | Description | Published |
---|---|---|
20140155385 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS - The present invention relates to 6-5 membered fused pyridine ring compounds according to formula (I) or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds according to formula I in the treatment of Brutons Tyrosine Kinase (Btk) mediated disorders. | 06-05-2014 |
20140155406 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES BTK INHIBITORS - The present invention relates to 6-5 membered fused pyridine ring compounds of formula (I) or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders. | 06-05-2014 |
Arthur A. Pershall, Kalispell, MT US
Patent application number | Description | Published |
---|---|---|
20080315584 | Engine start system with a regulated permanent magnet machine - An electromechanical power transfer system that transfers power between a direct current (DC) electrical power system and a prime mover, comprises: a permanent magnet machine (PMM) comprising a permanent magnet (PM) rotor that rotates a drive shaft of the prime mover, a stator with a multiphase alternating current (AC) winding coupled to the AC bus for developing a rotating magnetic field with a magnetic flux path that causes rotation of the PM rotor and a control coil with a winding that has a configuration to generate a magnetic field with flux that varies the reactance of the stator winding upon the application of current through the control coil; a plurality of AC current sensors for sensing the current in each phase of the multi-phase AC bus and generating respective AC bus current signals that represent the current level of each phase; an average current detector that receives the AC bus current signals and generates a respective current load feedback signal; a back electromotive force (emf) detector coupled to the AC bus that detects back emf generated by the stator in response to the application of AC power to the stator and generates a back emf signal representative of the detected level of back emf; a rotor position/speed estimator that receives the back emf signal and generates an estimated rotor position signal that is representative of the position of the rotor, an estimated rotor speed signal that is representative of the speed of the rotor and a closed loop enable signal that indicates a speed for the electrical starting system to switch from an open loop mode of operation to a closed loop mode of operation; a control coil current sensor for generating a control coil current signal in a control coil current feedback loop that is representative of the level of electrical current in the control coil; a first speed switch that switches between an open loop position reference signal that represents a desired position of the rotor in an open loop mode and the estimated rotor position signal that represents the position of the rotor in a closed loop mode to provide a position reference signal; a second speed switch that switches between an open loop current reference signal that represents a desired control coil current level in the open loop mode and a closed loop current reference signal that represents a desired control coil current level in the closed loop mode to provide a control coil current reference signal; an inverter/rectifier system for converting DC power from the DC power system to multiphase alternating current (AC) power on an AC bus; a control coil current regulator system for regulating current through the control coil; wherein the inverter/rectifier system responds to the position reference signal, the current load feedback signal and a current load reference signal to regulate acceleration of the PMM; wherein the control coil current regulator system responds to the control coil current reference signal and the control coil current feedback signal to regulate current in the PMM; and wherein the power transfer system starts in the open loop mode, the rotor position/speed estimator generates the closed loop enable signal that indicates a speed for the electrical starting system to switch from the open loop mode of operation to the closed loop mode of operation at a predetermined rotor speed, and the first and second speed switches respond to the closed loop enable mode to switch from their open loop mode to their closed loop mode. | 12-25-2008 |
Arthur A. Pille, Oakland, NJ US
Patent application number | Description | Published |
---|---|---|
20100179373 | Electromagnetic treatment apparatus and metod for angiogensis modulation of living tissues and cells - An apparatus and method for electromagnetic treatment of living tissues and cells comprising: configuring at least one waveform according to a mathematical model having at least one waveform parameter, said at least one waveform to be coupled to a angiogenesis and neovascularization target pathway structure; choosing a value of said at least one waveform parameter so that said at least waveform is configured to be detectable in said angiogenesis and neovascularization target pathway structure above background activity in said target pathway structure; generating an electromagnetic signal from said configured at least one waveform; and coupling said electromagnetic signal to said angiogenesis and neovascularization target pathway structure using a coupling device. | 07-15-2010 |
Arthur A. Tarricone, Jr., Ellicot City, MD US
Patent application number | Description | Published |
---|---|---|
20120331531 | CUSTOM DATA IMAGE BUILDING - A first server is configured to receive an image from a first client device. The image may include an instruction to provide a second client device with a computer file. The first server is further configured to store the image, receive a task query from the first client device, and provide a task query response to the first client device based on receiving the task query. The task query response may include an indication that the first server is storing a task associated with the second client device. The first server is further configured to receive an image request from the second client device, communicate with a second server to identify whether the second client device is authorized to receive the image, and provide, to the second client device, the computer file associated with the image based on identifying that the second client device is authorized to receive the image. | 12-27-2012 |
Arthur A. Tarricone, Jr., Ellicott City, MD US
Patent application number | Description | Published |
---|---|---|
20090183149 | DATA IMAGING SYSTEM AND METHODS - A method performed by a network device may include receiving index information from a second network device identifying an updated application, querying a third network device for the identified updated application, receiving the identified updated application from the third network device, storing the identified updated application received from the third network device and applying stored application user settings from memory to the stored updated application. | 07-16-2009 |
Arthur A. Vandenbark, Portland, OR US
Patent application number | Description | Published |
---|---|---|
20080267987 | Recombinant MHC Molecules Useful For Manipulation Of Antigen-Specific T-Cells - Two-domain MHC polypeptides useful for manipulation of antigen-specific T-cells are disclosed. These polypeptides include MHC class II-based molecules that comprise covalently linked β1 and α1 domains, and MHC class I-based molecules that comprise covalently linked α1 and α2 domains. These polypeptides may also include covalently linked antigenic determinants, toxic moieties, and/or detectable labels. The disclosed polypeptides can be used to target antigen-specific T-cells, and are useful, among other things, to detect and purify antigen-specific T-cells, to induce or activate T-cells, and to treat conditions mediated by antigen-specific T-cells. | 10-30-2008 |
20090010885 | Methods for Detecting and Treating Autoimmune Disorders - The present disclosure relates to methods for inhibiting an autoimmune disease by administering to a subject a therapeutically effective amount of a composition that increases FOXP3 expression, thereby inhibiting the autoimmune disease. Further disclosed herein are methods for detecting in a subject an autoimmune disease or a predisposition to an autoimmune disease, and methods for assessing the efficacy of a therapy for an autoimmune disease. | 01-08-2009 |
20100279401 | T Cell Hybridomas And Related Compositions And Methods For Assaying And Modulating T Cell Receptor-Mediated Immune Responses - The present invention provides T cell hybridomas and related compositions and assay systems for investigative, diagnostic, and therapeutic use in modulating T cell receptor (TCR)-mediated immune response. The T cell hybridomas of the invention are typically constructed by fusing a naïve or early central memory T cell isolated from a mammalian subject with an immortalizing fusion partner (e.g. mammalian lymphoid tumor cell) to yield clonal T cell hybrids. The resulting T cell hybridomas exhibit antigen (Ag)-specific proliferation responsiveness over a background level of proliferation of the hybridomas. These hybridomas are useful for screening, identifying, and characterizing T cell immune modulatory agents, for example recombinant T cell receptor ligands (RTLs) and other agents that can modulate TCR-mediated T cell immune responses. Ag-specific proliferative response profiles exhibited by the T cell hybridomas of the invention show sufficient amplitude, sensitivity and fidelity to distinguish and/or quantify the presence and/or activity of a test RTL or other test modulatory agent in screening and sensitivity assays employing the hybridomas. These and other aspects of the invention yield powerful tools and methods for developing and characterizing novel RTLs and other immune modulatory agents for use in treating immune disorders, including a wide range of autoimmune diseases, in mammals. | 11-04-2010 |
20110217308 | Compositions and methods using recombinant MHC molecules for the treatment of stroke - Two-domain MHC polypeptides are useful for modulating activities of antigen-specific T-cells, including for modulating pathogenic potential and effects of antigen-specific T-cells. Exemplary MHC class II-based recombinant T-cell ligands (RTLs) of the invention include covalently linked β1 and α1 domains, and MHC class I-based molecules that comprise covalently linked α1 and α2 domains. These polypeptides may also include covalently linked antigenic determinants, toxic moieties, and/or detectable labels. The disclosed polypeptides can be used to target antigen-specific T-cells, and are useful, among other things, to detect and purify antigen-specific T-cells, to induce or activate T-cells, to modulate T-cell activity, including by regulatory switching of T-cell cytokine and adhesion molecule expression, to treat conditions mediated by antigen-specific T-cells, including treatment and/or prevention of central nervous system damage relating to stroke. | 09-08-2011 |
20110262479 | RECOMBINANT MHC MOLECULES USEFUL FOR MANIPULATION OF ANTIGEN-SPECIFIC T-CELLS - Two-domain MHC polypeptides useful for manipulation of antigen-specific T-cells are disclosed. These polypeptides include MHC class II-based molecules that comprise covalently linked β1 and α1 domains, and MHC class I-based molecules that comprise covalently linked α1 and α2 domains. These polypeptides may also include covalently linked antigenic determinants, toxic moieties, and/or detectable labels. The disclosed polypeptides can be used to target antigen-specific T-cells, and are useful, among other things, to detect and purify antigen-specific T-cells, to induce or activate T-cells, and to treat conditions mediated by antigen-specific T-cells. | 10-27-2011 |
20120195921 | RECOMBINANT T-CELL RECEPTOR LIGAND FOR THE TREATMENT OF COGNITIVE AND NEUROPSYCHIATRIC IMPAIRMENT INDUCED BY SUBSTANCE ADDICTION - Methods are provided for the treatment of subjects with cognitive or neuropsychiatric impairment induced by substance addiction and for increasing cognitive function in a subject with substance addiction. In some embodiments, the methods include administering to the subject a therapeutically effective amount of a major histocompatibility complex (MHC) molecule including covalently linked first, second, and third domains; wherein the first domain is an MHC class II β1 domain and the second domain is an MHC class II α1 domain; or wherein the first domain is an MHC class I α1 domain and the second domain is an MHC class I α2 domain; and wherein the third domain is covalently linked to the first domain and comprises an antigen of the central or peripheral nervous system. | 08-02-2012 |
20120276127 | TREATMENT OF RETINAL DISORDERS WITH RECOMBINANT T CELL RECEPTOR LIGAND (RTL) - Methods are provided for the treatment of a retinal disorder or optic neuritis in a subject. In some embodiments, the methods include administering a therapeutically effective amount of an MHC molecule including covalently linked first, second, and third domains; wherein the first domain is an MHC class II β1 domain and the second domain is an MHC class II α1 domain, wherein the amino terminus of the α1 domain is covalently linked to the carboxy terminus of the β1 domain; or wherein the first domain is an MHC class I α1 domain and the second domain is an MHC class I α2 domain, wherein the amino terminus of the α2 domain is covalently linked to the carboxy terminus of the α1 domain; and wherein the third domain is covalently linked to the first domain and comprises a retinal antigen or an antigen of the central or peripheral nervous system. | 11-01-2012 |
20130190221 | MONOMERIC RECOMBINANT MHC MOLECULES USEFUL FOR MANIPULATION OF ANTIGEN-SPECIFIC T-CELLS - The present invention provides, in particular embodiments, for modified recombinant T cell receptor (TCR) ligands (RTLs) comprising a MHC class I or MHC class II component. The modified RTLs have redesigned surface features that preclude or reduce aggregation, wherein the modified molecules retain the ability to bind Ag-peptides, target antigen-specific T cells, inhibit T cell proliferation in an Ag-specific manner and have utility to treat, inter alia, autoimmune disease and other conditions mediated by antigen-specific T cells in vivo. | 07-25-2013 |
20130273087 | RECOMBINANT T-CELL RECEPTOR LIGAND FOR THE TREATMENT OF COGNITIVE AND NEUROPSYCHIATRIC IMPAIRMENT INDUCED BY SUBSTANCE ADDICTION - Methods are provided for the treatment of subjects with cognitive or neuropsychiatric impairment induced by substance addiction and for increasing cognitive function in a subject with substance addiction. In some embodiments, the methods include administering to the subject a therapeutically effective amount of a major histocompatibility complex (MHC) molecule including covalently linked first, second, and third domains; wherein the first domain is an MHC class II β1 domain and the second domain is an MHC class II α1 domain; or wherein the first domain is an MHC class I α1 domain and the second domain is an MHC class I α2 domain; and wherein the third domain is covalently linked to the first domain and comprises an antigen of the central or peripheral nervous system. | 10-17-2013 |
20130309229 | RECOMBINANT T CELL LIGANDS AND ANTIBODIES THAT BIND B CELLS FOR THE TREATMENT OF AUTOIMMUNE DISEASES - Methods are disclosed for treating or inhibiting an autoimmune disease in a subject. In some embodiments, the disclosed methods include administering to the subject a therapeutically effective amount of one or more Major Histocompatibility Complex (MHC) molecules including covalently linked first, second and third domains; wherein the first domain is an MHC class II β1 domain and the second domain is an MHC class II α1 domain, wherein the amino terminus of the α1 domain is covalently linked to the carboxy terminus of the β1 domain; or wherein the first domain is an MHC class I α1 domain and the second domain is an MHC class I α2 domain, wherein the amino terminus of the α2 domain is covalently linked to the carboxy terminus of the α1 domain; and wherein the third domain is covalently linked to the first domain and comprises an antigen associated with the autoimmune disorder. The method also includes administering a therapeutically effective amount of one or more antibodies that bind to B cells, for example an antibody that specifically binds CD20. In specific non-limiting examples, the autoimmune disease is multiple sclerosis or rheumatoid arthritis. | 11-21-2013 |
20140056936 | COMPOSITIONS AND METHODS USING RECOMBINANT MHC MOLECULES FOR THE TREATMENT OF STROKE - Two-domain MHC polypeptides are useful for modulating activities of antigen-specific T-cells, including for modulating pathogenic potential and effects of antigen-specific T-cells. Exemplary MHC class II-based recombinant T-cell ligands (RTLs) of the invention include covalently linked β1 and α1 domains, and MHC class I-based molecules that comprise covalently linked α1 and α2 domains. These polypeptides may also include covalently linked antigenic determinants, toxic moieties, and/or detectable labels. The disclosed polypeptides can be used to target antigen-specific T-cells, and are useful, among other things, to detect and purify antigen-specific T-cells, to induce or activate T-cells, to modulate T-cell activity, including by regulatory switching of T-cell cytokine and adhesion molecule expression, to treat conditions mediated by antigen-specific T-cells, including treatment and/or prevention of central nervous system damage relating to stroke. | 02-27-2014 |
20140170168 | ANTIBODIES WHICH BIND SOLUBLE T-CELL RECEPTOR LIGANDS - Provided are isolated high affinity entities which comprise an antigen binding domain which specifically binds a soluble T-cell receptor ligand comprising a two-domain beta1-alpha1 of a major histocompatibility complex (MHC) class II, wherein said antigen binding domain does not bind a complex comprising a four-domain alpha1-beta1/alpha2-beta2 MHC class II. Also provided are methods and kits using same for detecting and sequestering soluble two-domain T cell receptor ligands in a sample. | 06-19-2014 |
20150037363 | RECOMBINANT T-CELL RECEPTOR LIGAND FOR THE TREATMENT OF COGNITIVE AND NEUROPSYCHIATRIC IMPAIRMENT INDUCED BY SUBSTANCE ADDICTION - Methods are provided for the treatment of subjects with cognitive or neuropsychiatric impairment induced by substance addiction and for increasing cognitive function in a subject with substance addiction. In some embodiments, the methods include administering to the subject a therapeutically effective amount of a major histocompatibility complex (MHC) molecule including covalently linked first, second, and third domains; wherein the first domain is an MHC class II β1 domain and the second domain is an MHC class II α1 domain; or wherein the first domain is an MHC class I α1 domain and the second domain is an MHC class I α2 domain; and wherein the third domain is covalently linked to the first domain and comprises an antigen of the central or peripheral nervous system. | 02-05-2015 |
20150044245 | PARTIAL MHC CONSTRUCTS AND METHODS OF USE - Disclosed herein are isolated major histocompatibility complex (MHC) class II α1 domain polypeptides and methods of use. In some embodiments, the isolated polypeptide comprises or consists of an MHC class II α1 domain polypeptide (or portion thereof) and does not include an MHC class II α2, β1, or β2 domain. The disclosed MHC class II α1 domain polypeptides are of use in treating or inhibiting disorders in a subject, such as inflammatory and/or autoimmune disorders. Also disclosed are methods of evaluating efficacy of treatment or optimizing treatment of a subject with a polypeptide including an MHC class II α1 domain polypeptide (or portion thereof) or a polypeptide including an MHC class II α1 domain and β1 domain (such as a β1α1 RTL). | 02-12-2015 |
Arthur A. Woerheide, New York, NY US
Patent application number | Description | Published |
---|---|---|
20140330701 | Methods and Systems for Chart Based Order Entry - In one aspect, the invention comprises software comprising: (a) software for displaying a chart display comprising pricing information for securities; and (b) software for displaying an interface display for placing securities orders, wherein the chart display is configured to enable a user to enter price information in the interface display by selecting a location on the chart display corresponding to a price to be entered into the interface display. In another aspect, the invention comprises a method comprising entering price information in an interface display for placing securities orders by selecting a location on a chart display comprising pricing information for securities, the location corresponding to a price to be entered into the interface display. | 11-06-2014 |
Arthur A. Wright, Beckley, WV US
Patent application number | Description | Published |
---|---|---|
20100187398 | LAWN MOWER TILT TOOL - A tool and method for holding a rotary lawnmower in a tilted position to expose the underside of its deck for maintenance, comprising a bracket having an anchoring portion and a receiving pocket joined to the anchoring portion, the anchoring portion being adapted to be operatively mounted on a vertical wall or post surface or held down at or near a floor or ground level, the receiving pocket being arranged when the anchoring portion is operatively mounted to receive a horizontal hand grip of the distal end of a lawnmower handle, and a lock member deployable on said bracket to selectively retain or release the hand grip in or from the receiving pocket. | 07-29-2010 |